Prostate Cancer as a Model System for Genetic Diversity in Tumors
Jeremy A. Squire(Universidade de São Paulo), Anthony M. Joshua(St Vincent's Hospital Sydney), Andrew Evans(University of Dundee), Paul C. Park, Jennifer Alami(Queen's University), Maisa Yoshimoto(University of Alberta), Julia L. Williams(Queen's University)
Cited by 35
Related Papers
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
|The Lancet|2014|1.8k
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
|JAMA|2016|1.1k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869